Partner Steve Maebius contributed an article to Pharmaceutical Executive, “New Challenge to IP Innovation,” on August 31, 2016. The article provided an overview of the use of Inter Partes Reviews (IPRs) in the pharmaceutical industry, for both generic and originator companies. Maebius discussed the findings of a survey that analyzed 111 IPR filings by generic drug companies against pharmaceutical patents and highlighted key considerations for originator companies.
Author(s)
Related Insights
21 May 2025
Tariff & International Trade Resource
What Every Multinational Company Should Know About … Customs Enforcement and False Claims Act Risks (Part III)
We complete the series on “Customs Enforcement and False Claims Act Risks” with Part III, which focuses on preparing for the most common FCA risks arising from improper management of import operations.
02 June 2025
Events
Biotech Panel Discussion & Happy Hour
Join Foley & Lardner LLP along with Biotech XYZ for an engaging evening event featuring a dynamic panel discussion and a lively happy hour.
03 June 2025
Events
Biotech Breakfast + Office Hours
Join Foley & Lardner LLP along with Biotech XYZ for Phase Capitals’ flagship networking biotech breakfast and office hours with Q&A sessions.